Other Vaccines - Germany

Germany

Highlights

In Germany, the revenue in the Other Vaccines market is estimated to reach US$1.87bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 10.29%, leading to a market volume of US$3.06bn by 2029.
In terms of global comparison, United States is projected to generate the highest revenue, amounting to US$24.73bn in 2024.
Germany is a frontrunner in the development and distribution of other vaccines, with a strong emphasis on research and collaboration with pharmaceutical companies.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Germany has seen significant growth in recent years, driven by several factors.

Customer preferences: German consumers are becoming increasingly aware of the importance of vaccination in preventing disease and are more willing to invest in preventative healthcare. This trend is particularly evident in the Other Vaccines market, which includes vaccines for diseases such as meningitis, shingles, and HPV.

Trends in the market: One of the key trends in the Other Vaccines market in Germany is the increasing demand for combination vaccines, which offer protection against multiple diseases in a single shot. This trend is driven by a desire for convenience and cost-effectiveness, as well as concerns about vaccine hesitancy and the need to ensure that individuals receive all necessary vaccinations.Another trend in the Other Vaccines market in Germany is the growing focus on adult vaccination. While many vaccines are traditionally associated with childhood immunization, there is increasing recognition that adults also need protection against a range of diseases. This trend is particularly relevant in Germany, where the population is aging and there is a growing need for preventative healthcare.

Local special circumstances: Germany has a strong healthcare system with a focus on preventative care, which has helped to drive demand for vaccines. Additionally, the country has a high level of public trust in vaccines and a well-established vaccination program, which has helped to create a favorable environment for the Other Vaccines market.

Underlying macroeconomic factors: The German economy has been relatively strong in recent years, which has helped to support demand for healthcare services, including vaccination. Additionally, the country has a large and aging population, which has contributed to the growing focus on preventative healthcare and the need for vaccines. Finally, Germany has a highly developed healthcare infrastructure, which has helped to facilitate the distribution and administration of vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.